Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18344757 | 1.00 | L3MBTL1 (0.46) | L3MBTL1GPR119 | |
| SCHEMBL20336746 | 1.00 | L3MBTL1 (0.46) | L3MBTL1GPR119 | |
| SCHEMBL20336679 | 0.94 | L3MBTL1 (0.45) | L3MBTL1GPR119 | |
| SCHEMBL20336678 | 0.94 | L3MBTL1 (0.45) | L3MBTL1GPR119 | |
| SCHEMBL20336676 | 0.94 | L3MBTL1 (0.45) | L3MBTL1GPR119 | |
| SCHEMBL20336711 | 0.91 | GRK2 (0.52) | — | |
| SCHEMBL20336713 | 0.91 | GRK2 (0.52) | — | |
| SCHEMBL18344919 | 0.90 | L3MBTL1 (0.48) | L3MBTL1 | |
| SCHEMBL20336742 | 0.90 | L3MBTL1 (0.44) | L3MBTL1 | |
| SCHEMBL20336740 | 0.90 | L3MBTL1 (0.44) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313396-B1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2021-12-15 | — | — | EP | disclosed |
| US-10329283-B2 | G protein-coupled receptor kinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180186779-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-07-05 | — | — | US | disclosed |
| EP-3313396-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | The Regents of The University of Michigan (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210403-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329283-B2 | G protein-coupled receptor kinase inhibitors and methods for use of the same | GRK2, GRK4, GRK3 | L3MBTL1 4321/4885GPR119 182/4885 |
| US-20180186779-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | GRK2, GRK4, GRK3 | L3MBTL1 4321/4885GPR119 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.